Inimmune reports dosing of first patient in Phase 2 allergen challenge chamber trial of INI-2004
Gesynta Pharma doses first patient in vipoglanstat Phase 2 clinical proof-of-concept trial
Immunic granted European patent for vidofludimus calcium dosing regimens
Biofrontera reports Phase 2b data for Ameluz photodynamic therapy in acne vulgaris treatment
Pfizer reports positive Phase 2 results for trispecific antibody in atopic dermatitis
Kelun-Biotech and Harbour BioMed receive China IND approval for atopic dermatitis therapy
Melodia Therapeutics reports award of US patent covering MLD-151
GSK to acquire 35Pharma for USD950m to strengthen cardiopulmonary pipeline
Gossamer Bio reports topline Phase 3 PROSERA results for seralutinib in PAH
Formosa Pharmaceuticals signs licensing deal with Arrotex for APP13007 in Australia and New Zealand
Merck and Mayo Clinic launch AI-driven drug discovery collaboration
Palisade Bio makes Clinical Advisory Board appointment
STADA and Bio-Thera Solutions receive European marketing authorisation for Gotenfia (golimumab)
Hoth Therapeutics granted US patent for novel exon-skipping therapy targeting allergic diseases
DifGen Pharmaceuticals' Fluorometholone Ophthalmic Suspension, 0.1% receives FDA approval